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Sir,
We welcomed the response and debate regarding treatment-
related costs in metastatic renal cell carcinoma (RCC) provided
by Charbonneau (Pfizer, USA) and Sandin (Pfizer, Sweden)
(Charbonneau and Sandin, 2010). However, there are several
points in their letter we would like to address.
Novel therapies for the treatment of metastatic RCC have
different tolerability profiles, which are largely based on differ-
ences in mechanism of action (Schmidinger and Zielinski, 2009).
Side effects of therapy may have a different impact on individual
patients, with the potential to disrupt well-being, daily activities/
function and overall quality of life. The management of side effects
is a concern for physicians due to the potential for temporary or
permanent withdrawal of therapy to manage side effects, meaning
that patients may receive a suboptimal treatment benefit. The
management of side effects also represents additional costs for
payers and contributes to the total cost of therapy.
Two of the standard first-line treatment options for patients
with metastatic RCC, bevacizumabþIFN and sunitinib, have
largely different safety profiles. Vascular endothelial growth factor
(VEGF)-related side effects such as hypertension are observed with
both therapies, but non-VEGF-related side effects such as hand-
foot syndrome are also seen in patients treated with sunitinib
(Escudier et al, 2007; Motzer et al, 2007). Our original paper
outlined that bevacizumabþIFN is associated with lower adverse
event management costs than sunitinib, largely based on the
difference in tolerability profiles. These data are supported by
another recent analysis of healthcare costs in the United States that
reported that the adverse event management costs for bevacizumab
are 2–3 times lower than those for sunitinib (Oh et al,2 0 1 0 ) .
One point that we would like to reiterate is that there is strong
evidence to indicate that bevacizumabþIFN has similar efficacy
to sunitinib in patients with metastatic RCC. The two pivotal
trials for these therapies in metastatic RCC showed that both
bevacizumabþIFN and sunitinib significantly improved progres-
sion-free survival (PFS) compared with IFN, with a median PFS
of 10.2 and 11.0 months, respectively. Furthermore, a robust
meta-analysis performed by the Cochrane Collaboration concluded
that bevacizumabþIFN provides similar efficacy to sunitinib in
untreated patients with metastatic RCC (Coppin et al, 2008).
In our original publication, we addressed the papers by
Thompson-Coon et al and Mills et al, both of which suggested
that sunitinib is significantly more efficacious than bevacizumabþ
IFN (Mills et al, 2009; Thompson Coon et al, 2009). A signi-
ficant limitation of these analyses is the inclusion of data for
bevacizumabþIFN from CALGB 90206, an open-label phase III trial
with some important differences in patient demographics compared
with AVOREN. We argue that a valid indirect comparison of PFS
should only use the pivotal trial data, performed under the same
conditions and providing the same quality of data (independent
radiology review of PFS from controlled, blinded studies that are not
comparable to open-label studies). Furthermore, a recent analysis of
independently assessed PFS data from AVOREN and the phase III
sunitinib trials reported that there is no significant difference in
first-line PFS between sunitinib and bevacizumabþIFN (HR¼0.94
(95% CI: 0.69–1.29; P¼0.709)) (Mickisch et al,2 0 1 0 a , b ) .
Additionally, repeating the Mills et al, analysis, which is more
conservative than the Thompson Coon analysis, with the
investigator assessing data from the pivotal trials of sunitinib
and bevacizumabþIFN results in a non-significant PFS HR of 0.83
(95% CI: 0.64–1.06; P¼0.13) (Mickisch et al, 2009a,b).
It is well recognised that non-VEGF-related side effects such as
fatigue, GI events, HFSR, myelosuppression, diarrhoea, mucositis
and rash, although often not severe, can have an impact on the
patient’s quality of life (Porta and Szczylik, 2009). Therefore, an
ability to effectively manage side effects and get patients and/or
carers back to work may represent a hidden cost benefit that has
not been addressed in cost-related analyses to date and should help
to reduce health-related costs.
As we outlined in our paper, adverse event management costs
vary for each country and for each side effect. For example,
haematological adverse events, which are reported more frequently
with sunitinib than with bevacizumab, are likely to have the
highest management costs and therefore a greater impact on the
total adverse event management costs. Another consideration is
that some adverse events may be experienced for prolonged
periods and may require repeated treatment measures, which may
not be captured by an analysis such as ours.
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overestimated the costs associated with the management of some
adverse events, based on a lower cost for the treatment of grade 3/4
thrombocytopenia reported in the latest UK National Health
Service costs (2010). This observation is correct as we used an
older version of the UK National Health Service costs (NHS
reference costs 2006–2007), based on the timing for development
and submission of our original paper. However, the reported
incidence of grade 3/4 thrombocytopenia with sunitinib is higher
than that seen with bevacizumabþIFN and therefore the
proportional cost for this side effect will remain higher for
patients treated with sunitinib.
Overall, treatment-related costs are likely to include acquisition
costs, administration costs and costs related to the management of
adverse events. Drug acquisition costs will evidently vary due to
country-specific initiatives agreed between the healthcare autho-
rities and pharmaceutical companies. In consequence, overall
treatment costs are not a primary consideration if looking at cross-
country trends and differences as a scientific objective. In contrast,
secondary costs such as costs associated with the treatment of
adverse events are directly related to the drug involved and largely
independent of the pricing strategies of the manufacturer. We
agree that the management of adverse event costs is comparatively
small compared with that of acquisition costs. However, adverse
events and their management may substantially impact on patient
quality of life, remain independent of the acquisition costs and
hinder physician care. This is most important from a clinician’s
point of view.
Taking into account all healthcare-related costs, including any
differences in drug acquisition costs and costs related to the
management of adverse events, an analysis of healthcare costs
based on the Italian healthcare system reported comparable annual
costs for bevacizumabþIFN and sunitinib (Ravasio, 2009). Moreover,
an analysis based on healthcare costs in the United Kingdom by
the National Institute of Clinical Excellence (NICE) reported that
bevacizumabþIFN and sunitinib had comparable incremental cost-
effectiveness ratios: d53820 and d50000, respectively (NICE, 2009).
The management of adverse events has important implications
for patients, physicians and payers. In the absence of direct head-
to-head clinical assessment, a model such as ours is currently
the only available way to assess the costs associated with the
management of adverse events, which may help to facilitate the
decision-making process.
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